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Abstract 
 
Atherosclerotic renal artery stenosis is the leading cause of secondary 
hypertension; it can also cause progressive renal insufficiency and cardiovascular 
complications such as refractory heart failure and flash pulmonary edema. Medical 
therapy including risk factor modification, renin-angiotensin-aldosterone system 
antagonists, lipid lowering agents and antiplatelet therapy is the first line of treatment in 
all patients. Patients with uncontrolled renovascular hypertension despite optimal medical 
therapy, ischemic nephropathy and cardiac destabilization syndromes who have severe 
renal artery stenosis are likely to benefit from renal artery revascularization. Screening 
for RAS can be done with Doppler ultrasonography, computed tomographic angiography 
and magnetic resonance angiography. Invasive physiologic measurements are useful to 
confirm the severity of renal hypoperfusion and therefore improve the selection patients 
likely to respond to renal artery revascularization. Primary patency exceeds 80% at 5 
years and surveillance for in-stent restenosis can be done with periodic clinical, 
laboratory, and imaging follow up. 
 
 
Introduction 
Atherosclerotic renal artery stenosis (ARAS) accounts for >90% of cases of renal 
artery stenosis and it is most commonly seen in patients >65 years old. It is an 
independent predictor of death in patients with coronary artery disease
1
.  However, the 
cause-and-effect relation between RAS and mortality remains unproven. The presence of 
ARAS may be a marker for more diffuse or extensive atherosclerosis, which would result 
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in more vascular related deaths. However, patients who improve their renal function after 
percutaneous renal artery stent (PTRAS) placement have significantly better survival 
rates compared with those who do not improve
2
.  
Managing patients with ARAS remains complex, particularly since several 
randomized controlled trials (RCTs) have not to shown superiority of an initial strategy 
of revascularization over OMT in terms of BP control, preservation of renal function or 
major cardiovascular or renal events. For those who fail optimal medical therapy 
(resistant hypertension), PTRAS remains an appropriate strategy.  
Based on the conclusions of randomized trials, one might think that the question 
of how to manage ARAS has been answered. However, each of these trials had its own 
limitations that ranged from their inclusion criteria to their interpretation that limit their 
applicability to every day practice. All of the trials excluded patients with advanced 
kidney disease, resistant hypertension, malignant or accelerated HTN, history of 
refractory heart failure (HF) or a recent acute coronary syndrome. As is typical of 
randomized trials, the data may not be directly applicable to "real world" patients with the 
highest risk presentations of atherosclerotic renovascular disease, including flash 
pulmonary edema, rapidly declining kidney function, or refractory hypertension.  These 
highest risk patients, may not have been considered candidates for the conservative arm 
of the trial, and thus not studied. 
Identifying patients at highest risk is the most important step when caring for 
patients with ARAS, since the failure to revascularize them can translate in significantly 
worse clinical outcomes, including mortality. In a prospective cohort of 467 patients with 
ARAS, those patients with flash pulmonary edema were at risk for both death (hazard 
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ratio [HR], 2.19; P , 0.001) and/or new cardiovascular events (HR, 3.07; P , 0.001) 
compared to the low-risk cohort. Those with flash pulmonary edema who underwent 
revascularization were at lower risk for death (HR, 0.43; P 5 0.01) than those who were 
managed medically. An additional small group (n 5 31) with both rapidly progressive loss 
of kidney function and refractory hypertension were more likely to survive with renal 
revascularization (HR, 0.15; P 5 0.04) 
3
.  
Clinical Syndromes Associated with RAS 
When selecting patients for PTRAS, clinical, anatomical and physiologic data 
should be considered to optimize the benefit of revascularization. The current data 
suggest that OMT should be used in all patients with ARAS.  In patients with refractory 
hypertension, despite OMT, revascularization remains an appropriate choice.  In patients 
with declining renal function and ARAS, revascularization is indicated to preserve renal 
function.  In patients with flash pulmonary edema or refractory heart failure and ARAS, 
revascularization is indicated in concert with OMT.  There continues to be a role for 
PTRAS when medical management alone has not been enough to control blood pressure 
or mitigate renal function loss
4
.  
ARAS is the single largest cause of secondary hypertension affecting 25-35% of 
the patients with secondary hypertension
5,6
, is associated with progressive renal 
insufficiency and causes cardiovascular complications such as refractory heart failure and 
flash pulmonary edema. Understanding the underlying pathophysiologic mechanisms, 
clinical manifestations, and medical or revascularization treatment strategies are 
necessary to optimize outcomes for ARAS patients.  A critical issue is the appropriate 
patient selection for revascularization procedures.  
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 In order to appropriately select patients who would benefit from revascularization, 
the clinician must understand the pathophysiology of renal hypoperfusion and the clinical 
conditions caused by it and should be able to identify ARAS as a bystander, not the cause 
of the clinical problem. ARAS can cause renovascular hypertension, ischemic 
nephropathy and cardiac destabilization syndromes (i.e. refractory heart failure and acute 
coronary syndromes). 
Renovascular hypertension: Renin-angiotensin-aldosterone system (RAAS) 
activation occurs with both unilateral and bilateral (or solitary) renal hypoperfusion. This 
leads to sodium retention, secondary hyperaldosteronism, vasoconstriction and adverse 
left ventricular remodeling. In unilateral RAS, the ischemic kidney secretes renin, 
causing increased angiotensin formation and increased blood pressure. As blood pressure 
rises, sodium excretion by the normal contralateral kidney increases, therefore, there is no 
sodium retention or subsequent volume overload.  With bilateral (or solitary) RAS, the 
lack of sodium excretion compensation from a normal kidney leads to fluid retention, loss 
of kidney function, and heart failure.  
Resistant or refractory hypertension due to RAS is defined as blood pressure above 
goal on three different classes of antihypertensive medications, ideally including a 
diuretic drug
7
. Patients with resistant hypertension should be evaluated for secondary 
causes of hypertension.  Studies of refractory hypertension commonly reveal a high 
prevalence of previously unrecognized ARAS, particularly in older patient groups. In 
patients older than 50 years of age who were referred to a hypertension center 13% had a 
secondary cause of hypertension, the most common of which was ARAS
8
.   
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ARAS is a common finding in hypertensive patients undergoing cardiac 
catheterization for atherosclerotic coronary artery disease. In a population of veterans 
with hypertension referred for coronary angiography more than 20% of patients were 
found to have hemodynamically significant RAS (>70%)
9
. In a series of 1,089 renal 
arteries in 534 patients undergoing angiography with either uncontrolled hypertension or 
flash pulmonary edema, 19% were found to have significant ARAS at the time of 
coronary angiography
10
. 
Current ACC/AHA guidelines and the SCAI PAD Appropriate Use Criteria 
recommend PTRAS for patients with significant ARAS and resistant hypertension or in 
patients with hypertension and medication intolerance (Class IIa, LOE B and 
Appropriate)
11,12
. 
Ischemic nephropathy: ARAS is a potentially a reversible cause of renal 
insufficiency. As many as 11-14% of patients starting dialysis have potentially reversible 
ESRD that is attributable to ARAS
13
. Favorable predictors of improvement following 
revascularization include a rapid decline in renal function, worsening of renal function 
due to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers 
(ARB) treatment, kidney pole to pole length > 8.0 cm, absent glomerular or interstitial 
fibrosis on kidney biopsy, and the absence of proteinuria
14
.  In patients with chronic renal 
failure (eGFR < 50 mL/min) and clinical evidence of ARAS treated with PTRAS 
demonstrated improvement in renal function in 34 of 59 patients (57.6%). The most 
important predictor of improvement was a more rapid progression (rate of change) of 
their renal failure
15
.  
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Multiple small trials and case series have demonstrated recovery of renal function 
after a revascularization procedure even in patients with dialysis-dependent ESRD. In a 
retrospective series of 16 dialysis patients that underwent stenting for RAS, 8 patients 
were successfully withdrawn from dialysis
16
. Despite the small size and multiple 
limitations of available studies, their results suggest the presence of a subset of patients in 
whom hypoperfusion due to ARAS has progressed beyond the limit of renal adaptive 
capacity in kidneys that is reversible with revascularization. In patients with rapidly 
progressive renal dysfunction and evidence of a significant stenosis by non-invasive 
testing, PTRAS should be considered.  
The current AHA/ACC guidelines
12
 and the SCAI Appropriate Use Criteria for renal 
artery stenting 
11,17
 recommend PTRAS for patients with ischemic nephropathy if they 
have progressive chronic kidney disease (CKD) due to bilateral ARAS (Class IIa, LOE B 
and Appropriate), progressive CKD with ARAS to a solitary functioning kidney (Class 
IIa, LOE B and Appropriate) and CKD with unilateral ARAS (Class IIb, LOE C and May 
Be Appropriate). 
Cardiac destabilization syndromes:  The most widely recognized example of a 
cardiac destabilization syndrome is “flash” pulmonary or Pickering syndrome 18. ARAS 
causing uncontrolled hypertension and volume retention may destabilize patients with 
heart failure or acute coronary syndromes.  
We have analyzed the results of renal artery stent placement in another group of 48 
patients with unstable angina (n=23) or congestive heart failure (n=25) who had 
hypertension refractory to medical therapy and ≥ 70% stenosis of one (n=30) or both 
(n=18) renal arteries 
19
.  Results of renal artery stenting for each subgroup are shown in 
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table 1.  For the entire cohort of patients, hypertension control was achieved within 24 
hours in 87% and a sustained benefit was seen in 74% at six months. 
 
The importance of renal artery revascularization in the treatment of cardiac 
disturbance syndromes has been described in a series of patients presenting with either 
congestive heart failure (CHF) or an acute coronary syndrome
20
. Successful PTRAS 
resulted in a significant decrease in blood pressure and symptom improvement in 88% 
(42 of 48) of patients. For those patients who presented with unstable angina, PTRAS 
improved the Canadian Cardiovascular Society (CCS) symptoms at least by one class 
regardless of whether concomitant coronary intervention was performed. In patients 
presenting with heart failure, the New York Heart Association (NYHA) Class of 
symptoms improved by at least one class with PTRAS, independent of coronary 
revascularization (Figure 1).  Among 207 patients with decompensated heart failure, 19% 
had severe ARAS and underwent PTRAS resulting in a decreased frequency of CHF 
admissions, flash pulmonary edema, and improved NYHA Class symptoms and tolerance 
to ACE inhibitors
20
. 
The current AHA/ACC guidelines
12
 and the SCAI PAD Appropriate Use Criteria
11
 
recommend PTRAS for ARAS with recurrent, unexplained heart failure decompensation, 
or sudden unexplained pulmonary edema (Class I, LOE B and Appropriate) and for 
hemodynamically significant ARAS and medically refractory unstable angina (Class IIa, 
LOE B and Appropriate). 
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Diagnostic Testing 
Doppler ultrasound evaluation: Renal artery Doppler ultrasound (DUS) carries a 
sensitivity of 97%, specificity of 81%, and negative predictive value of 95% for the 
detection of significant ARAS
21
.  The accuracy of this technology is highly dependent on 
the skill of the technician performing the examination and allowing adequate time for 
each examination. 
In a native renal artery, a peak systolic velocity (PSV) >180 cm/sec has a 95% 
sensitivity and 90% specificity for significant ARAS. When the ratio of the PSV of the 
stenosed renal artery to the PSV in the aorta is >3.5, DUS predicts >60% ARAS with a 
92% sensitivity
22
. DUS also allows follow up of stent patency in patients that have 
undergone PTRAS, however, the DUS criteria for native renal artery stenosis, 
overestimates the degree of angiographic in-stent restenosis (ISR) due to loss of 
compliance of the artery after stent placement. Surveillance monitoring for renal stent 
patency should take into account that PSV and renal artery resistive index (RI) obtained 
by DUS are higher for any given degree of arterial narrowing within the stent. PSV >395 
cm/s or RI >5.1 were the most predictive of angiographically significant ISR >70%
23
.  
DUS can be performed without risk to the patient, there is no iodinated contrast or 
ionizing radiation required. The main limitations for DUS include unsatisfactory exams 
due to overlying bowel gas or large body habitus. DUS may not identify accessory renal 
arteries.  Finally, there is a requirement for a skilled sonographer who is allowed enough 
time to perform the examination. 
Resistance index (RI) The resistance index, which is a calculated parameter 
derived from the renal DUS, is the ratio of the peak systolic to end diastolic velocity 
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within the renal parenchyma at the level of the cortical blood vessels. RI represents the 
amount of small-vessel arterial disease (nephrosclerosis) within the renal parenchyma. 
Some authors report that resistance index can be used to stratify patients according to 
how likely they are to respond to renal intervention. 
24,25
.  
In a small retrospective series (n=81 patients), an elevated RI (>80) was 
associated with a lower probability of blood pressure or renal function improvement after 
revascularization (PTA or open surgery)
26
. This study has not been replicated. A 
prospective study of PTRAS in 241 patients demonstrated that individuals with an 
elevated resistance index (>80) achieved a favorable BP response and renal functional 
improvement at one year after renal arterial intervention
24
. Another series demonstrated 
that patients with the most abnormal resistance index values experienced the greatest 
magnitude of benefit from PTRAS
25
. An elevated RI should not be considered a 
contraindication to performing renal artery revascularization.  
Computed tomographic angiography (CTA): CTA can provide high-resolution cross-
sectional imaging of ARAS while supplying 3D angiographic images of the aorta, renal, 
and visceral arteries allowing localization and enumeration of the renal arteries, including 
accessory branches 
27
. Sensitivity (59% to 96%) and specificity (82% to 99%) of CTA for 
detecting significant RAS compares well with invasive angiography
28
. CTA requires the 
administration of 100 to 150 mL of iodinated contrast and therefore carries the potential 
risk of contrast induced nephropathy (CIN) especially in patients with estimated 
glomerular filtration rate (eGFR)<60 mL/1.73m
2
, diabetes mellitus or anemia
29
. 
Additionally, CTA requires the use of ionizing radiation. However, as CTA scanner 
technology advances, spatial resolution will improve, scanning time will decrease, the 
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administered contrast load may be reduced and the amount of radiation will be 
decreased
30
. Additionally, iso-osmolar contrast media are now available with decreased 
potential for nephrotoxicity
31
. CTA may be used to follow patients for stent patency, an 
advantage over magnetic resonance angiography (MRA) in which metallic stents 
generate artifact
28
. 
Magnetic resonance angiography (MRA): This imaging modality allows localization 
and enumeration of the renal arteries and characterization of the stenosis. When 
compared to invasive angiography MRA has a sensitivity between 92 to 97% and 
specificity of 73 to 93% for detection of ARAS
32,33
. MRA does not require exposure to 
ionizing radiation or iodinated contrast material. Limitations for MRA include the 
requirement of gadolinium contrast with the associated risk of nephrogenic systemic 
fibrosis in patients with eGFR<30mL/1.73m
2
 and metal causes severe artifacts, therefore, 
it is not a useful test for patients with prior renal stents. Other patients who are not good 
candidates for MRA include those with claustrophobia or those with implanted 
ferromagnetic medical devices (e.g., artificial joints, permanent pacemakers)
34
.  
 
Treatment Strategies 
Medical management of RAS:  Optimal medical management of atherosclerotic 
vascular disease involves blood pressure control, lipid lowering therapy, an antiplatelet 
agent and lifestyle advice, including dietary counseling, smoking cessation and physical 
activity. Historically, the use of angiotensin converting enzyme inhibitors, (ACEI) or 
angiotensin receptor blockers, (ARB) was contraindicated in this patient group owing to 
concerns of worsening renal function. Concerns with renin-angiotensin-aldosterone 
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system antagonists in this patient group are probably overstated, and observational 
studies have shown improved outcomes using this class of medication, perhaps due to 
interruption on many pathophysiologic processes described above. When utilized 
prospectively, RAAS antagonists were tolerated in 357 of 378 patients (92%), and this 
was even seen in 54/69 (78.3%) patients with bilateral RAS (>60%) or occlusion
35
. A 
subsequent observational study, with 3,750 patients with renovascular disease found 53% 
were taking RAAS antagonists and these patients had significantly lower risk the primary 
outcome (death, myocardial infarction or stroke) [hazard ratio (HR) 0.70; 95 % 
confidence interval (CI) 0.53–0.90]36. The limitation of observational data is the selection 
bias, and those able to tolerate RAAS antagonists may have less severe disease and could 
have better outcomes anyway. Those patients who cannot tolerate medical therapy tend to 
have more extensive disease and are likely to benefit from revascularization
37
. Despite 
the lack of randomized trials, there is consensus that RAAS antagonists may be used in 
patients with ARAS; however, they should be carefully monitored and introduced slowly. 
Lipid lowering therapy is widely accepted as an important treatment for all 
atherosclerotic vascular disease
38
. In a retrospective study, statin therapy was associated 
with lesser rate of progression of renal insufficiency (7.4% vs. 38.9%) and lower overall 
mortality (5.9% vs. 36.1%), P <0.001 for both, with a mean follow up of 11 years, 
suggesting the need for prospective randomized controlled studies in renovascular disease 
patients in order to explore potential benefits of statins that may not be attributable solely 
to lipid lowering
39
. 
The use of antiplatelet agents and smoking cessation in patients with ARAS has 
the same benefits as in other forms of atherosclerotic disease including peripheral and 
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coronary artery disease.  The recently published The Cardiovascular Outcomes in Renal 
Atherosclerotic Lesions (CORAL) trial investigated the benefit of an initial strategy of 
optimal medical therapy (OMT) versus an initial strategy of PTRAS plus OMT in 
patients with hypertension and ARAS.  All patients received, unless contraindicated, the 
angiotensin II type-1 receptor blocker, candesartan, with or without hydrochlorothiazide, 
and the combination agent amlodipine–atorvastatin, with the dose adjusted on the basis of 
blood pressure and lipid status
40
. 
CORAL defined hypertension with a systolic blood pressure of 155 mm Hg or 
higher while receiving two or more antihypertensive medications (which is not refractory 
hypertension).  They also likely enrolled patietns with non-obstructive renal artery 
stenosies as they did not confirm the physiologic severity of moderate (50%-69%) 
stenoses with translesional gradients.  The primary composite endpoint (death from 
cardiovascular or renal causes, myocardial infarction, stroke, hospitalization for 
congestive failure, progressive renal insufficiency, or the need for renal replacement 
therapy) in patients with renal artery stenosis (> 60% diameter stenosis) did not differ 
between groups.  The final number of blood pressure medications was not different 
between the groups (OMT 3.5 ± 1.4 versus PTRAS 3.3 ± 1.5) at the completion of the 
trial and both groups had a similar reduction in systolic blood pressure, 15.6 ± 25.8 
mmHg in the OMT group and 16.6 ± 21.2 mmHg in the PTRAS group. CORAL confirms 
the ACC/AHA guideline recommendations
12
 and SCAI PAD Appropriate Use Criteria
11
 
that first line therapy for patients with newly discovered RAS and hypertension is a trial 
of OMT.  For those who fail OMT (resistant hypertension), PTRAS remains an 
appropriate strategy. 
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It is important to note that the CORAL trial does not apply to patients with 
resistant or refractory hypertension. CORAL did not investigate patients in whom 
medical therapy had failed to control blood pressure and therefore it will be unlikely to 
change the ACC/AHA recommendations for renal artery revascularization. Current 
ACC/AHA guidelines
12
 and SCAI PAD Appropriate Use Criteria
11
 recommend renal 
artery stenting for patientS with ARAS and accelerated or resistant hypertension or in 
patients with hypertension with medication intolerance (Class IIa, LOE B, Appropriate). 
Renal artery surgery: Surgical repair of ARAS was the only available 
revascularization option before renal artery angioplasty.  In an observational series 500 
patients with RAS and hypertension, managed with surgical revascularization and 
followed for up to 10 years, 12% of patients were cured of their hypertension and 73% 
were improved. Importantly, 30-day mortality ranged from 4.6% to 7.3%. Complications 
of surgery include surgical infections; surgery related bleeding, urinary tract infection, 
pseudomembranous colitis, amongst others. Today, PTRAS has largely replaced surgical 
renal revascularization for ARAS because of the increased morbidity and mortality 
associated with surgery. 
Renal artery stenting:  PTRAS is the standard of care for patients with 
hemodynamically significant renal artery stenosis (>70% angiographic diameter renal 
artery stenosis or 50% to 70% stenosis with a significant translesional gradient) and 1) 
resistant or uncontrolled hypertension and the failure of three antihypertensive drugs, one 
of which is a diuretic, or hypertension with intolerance to medication, 2) ischemic 
nephropathy and 3) cardiac destabilization syndromes.  These populations were not 
included in the CORAL trial.  
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Despite excellent angiographic outcomes achieved with renal stenting, there is a 
mismatch between angiographic (>97%) and clinical (~70%) success for controlling 
hypertension and renal dysfunction. In a meta-analysis of 14 studies (678 patients) 
evaluating PTRAS for either hypertension or CKD, the procedure success rate was 98% 
(95% CI 95% to 100%)
41
. However, the clinical improvement rate for hypertension was 
only 69%, with a cure rate of 20%, and a lowering of blood pressure in 49% (Figure 2A). 
Amongst patients with CKD, renal function improved in 30% and stabilized in 38% of 
patients with an overall favorable response rate of 68% (Figure 2B) 
41
.  The mismatch 
between angiographic success and clinical response may be explained by 1) the treatment 
of non-obstructive RAS lesions (visually over-estimating the stenosis severity), or 2) the 
symptoms (hypertension or CKD) were not caused by ARAS, i.e. essential hypertension. 
The key to improving the response rate and clinical outcomes after PTRAS is to better 
identify which patients are likely to benefit from intervention. 
Several recent randomized clinical trials have attempted to determine the clinical 
benefit of PTRAS. Unfortunately, both the STAR (Stent Placement in patients with 
atherosclerotic Renal artery Stenosis and Impaired Renal function ) and ASTRAL 
(Angioplasty and stenting for Renal artery Lesions ) trials were flawed by poor design 
and the inability to objectively assess the severity of the ARAS.  They failed to select 
patients with hemodynamically significant ARAS lesions that causes renal hypoperfusion 
and they also included inexperienced operators resulting in unusually high complication 
rates. 
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Selecting patients likely to benefit from revascularization 
With this mismatch between technical success and clinical response after PTRAS, 
the question is how to better select patients who are most likely to benefit from PTRAS. 
Unfortunately, angiography is not precise and and represents an uncertain "gold standard" 
for determining the hemodynamic severity of moderate (50% - 70%) RAS. There was a 
poor correlation between visual estimation of angiographic diameter stenosis in patients 
with RAS (50-90% diameter stenosis), and resting mean translesional pressure gradient 
(r=0.43; p=0.12); hyperemic mean translesional pressure gradient (r =0.22; p=0.44); and 
renal FFR (r=0.18; p=0.54) (Figure 3)
42
. Physiologic confirmation of the severity of 
moderate ARAS should be performed prior to PTRAS. 
Translesional pressure gradients: A resting translesional pressure ratio (Pd/Pa) of 
<0.90 or a hyperemic systolic gradient of >20 mmHg correlated with a significant renal 
hypoperfusion manifested by a rise in renin concentration in the ipsilateral renal vein
43,44
. 
Several series have shown improved blood pressure response when treating lesions with 
resting or hyperemic pressure gradients >20 mmHg
45,46
. Based on these observations, an 
expert consensus panel recommended that a resting or hyperemic translesional systolic 
gradient of at least 20 mmHg, or a resting or hyperemic mean pressure gradient of 10 
mmHg, be used to confirm the severity of lesions ≤70% diameter stenosis in symptomatic 
patients with RAS
47
. Because the catheter itself can introduce an artificial gradient
48
 
measurements should be done with either a 4Fr or smaller catheter or a 0.014” pressure 
wire
49
.  
Renal artery fractional flow reserve (FFR): Another method to determine the 
severity of angiographic RAS is to quantify the FFR. This hemodynamic assessment of 
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flow, which is widely used in the coronary circulation, is based on the principle that flow 
across a conduit artery is proportional to pressure across the vascular bed and inversely 
proportional to the resistance of the vascular bed. Under conditions of maximum 
hyperemia, the resistance of the vascular bed is at a minimum and constant, thereby 
maximizing flow. Any reduction in flow under these conditions is caused by a stenosis 
and is proportional to the ratio of pressure distal to the stenosis (Pd) and the pressure 
proximal to the stenosis (Pa).  
FFR is measured after induction of maximum hyperemia. Renal hyperemia can be 
achieved with papaverine
42,44
, dopamine
46
 or acetylcholine
50
.  Translesional pressure 
gradients are measured and FFR (Pd/Pa) is calculated using a 0.014'' pressure guidewire. 
Renal artery FFR correlates well with other hemodynamic parameters of lesion 
severity
44,51
 (Figure 4). In one study, renal FFR was measured after renal stent placement 
in 17 patients with refractory hypertension and moderate to severe (50–90% stenosis), 
unilateral ARAS. Ten patients had normal baseline renal FFR (defined as FFR≥0.80), 
whereas an abnormal baseline renal FFR (<0.80) was recorded in seven patients. At three 
months after intervention, 86% of patients with an abnormal renal FFR experienced 
improvement in their BP, compared with only 30% of those with normal renal FFR (p = 
0.04) Figure 5. In this small series, baseline systolic, mean, or hyperemic translesional 
pressure gradients were not different between patients whose BP improved and those in 
whom it did not
52
. 
Renal frame counts (RFC): In the coronary vasculature, the Thrombolysis in 
Myocardial Infarction (TIMI) frame count is a quantitative angiographic assessment of 
epicardial coronary blood flow that correlates with clinical outcomes 
53,54
.  The renal 
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frame count has been proposed as an alternative angiographic method to assess renal 
perfusion. RFC is the number of cine frames required for the contrast to reach the 
smallest visible distal branch in the renal parenchyma. As in TIMI frame counting, the 
first frame used for the RFC is the frame in which the contrast first fills the main renal 
artery. The last frame is when contrast enters the smallest visible branch of the distal 
renal parenchyma along the axis of the main renal artery. The measurements are done at 
30 frame/sec angiography.  
RFC was initially described in patients with fibromuscular dysplasia (FMD) of the 
renal arteries (15 kidneys), who were compared to subjects with normal renal arteries (50 
kidneys) and had a significantly higher (prolonged) mean RFC (26.9 vs. 20.4 
p=0.0001)
55
. In a prospective series of 24 patients with uncontrolled hypertension who 
underwent renal artery stenting, reduction in RFC after stenting was associated with BP 
reduction and >4 RFC reduction after stenting predicted BP reduction in 78% of 
subjects
56
. Patients with baseline RFC > 30 had a mean arterial pressure reduction of 23.8  
mmHg vs 11.8 mm Hg  (P < 0.001) when compared to patients with RFC ≤ 30. 
Furthermore, baseline RFC >30 was associated with a higher rate of clinical response to 
RA stenting (93.5% vs. 73%, P = 0.027)57 
Serum biomarkers: Brain natriuretic peptide (BNP) is a neurohormone released from 
the ventricular myocardium in conditions that cause myocardial cell stretching like 
congestive heart failure and pulmonary embolism
58
. BNP has been shown to directly 
correlate with pulmonary capillary wedge pressure
59
. In vitro studies have also shown 
that angiotensin II induces the synthesis and release of BNP, and in rats it has been found 
that BNP mRNA is upregulated 6 hours after clipping of the renal artery
60
.  
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In a series of 27 patients with significant RAS (>70% diameter stenosis) and 
uncontrolled hypertension, excluding patients with congestive heart failure, recent 
myocardial infarction and chronic renal insufficiency (Cr >=2) it was found that a 
baseline BNP>80 pg/mL and BNP decreased by at least 30% had a significant correlation 
with clinical improvement in blood pressure.  However, in the safety and efficacy of the 
RX HERCULink Elite renal Stent system (HERCULES) trial, a single-arm multicenter 
trial that included 202 patients with RAS and uncontrolled hypertension, BNP levels did 
not correlate with clinical improvement in blood pressure
61
. The usefulness of BNP as a 
predictor of good clinical outcome needs to be confirmed in a larger cohort of patients. 
Technical aspects of revascularization 
There are several important technical and procedural considerations to prevent 
complications during PTRAS. Selective renal angiography should be preceded by non-
selective abdominal aortography or non-invasive imaging with CTA or MRA.  
Techniques like catheter-in-catheter or no-touch should be used to minimize contact with 
the aortic wall and injury to the renal ostium during guiding catheter engagement. 
Adequate pre-procedure hydration and limiting contrast volume are helpful to prevent 
CIN.  
Radial access:  Radial artery access is increasingly used to perform percutaneous 
diagnostic and interventional coronary procedures to reduce access site bleeding 
complications and improve post-procedural patient comfort
62
. The radial approach for 
renal stenting represents a valuable tool to reduce access-site complications and improve 
patient’s comfort. However, the operator needs specific technical skills as well as 
knowledge of device compatibility. Both radial arteries are suitable for renal intervention. 
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Depending on the configuration of the aortic arch, the left radial access allows a shorter 
distance to renal arteries. The right radial approach is ergonomically more comfortable, 
with lower radiation exposure for the operator. The use of 125 cm long guiding catheters 
with 150 cm balloon/stent shafts are appropriate for almost all patients whereas the 100 
cm long catheters and 135 cm long balloon/stent shafts may not reach the renal arteries in 
taller patients or in patients with excessive aortic arch tortuosity
63
.  
Embolic protection devices (EPD): Atheroembolism has been associated with an 
increase in morbidity and a dramatic reduction in 5-year survival compared with patients 
who had no evidence on biopsy of renal atheroembolization (54% versus 85%, P = 
0.011)
64
. Since atheroembolism is a potential complication of PTRAS investigators have 
looked for the role of EPDs in optimizing outcomes after renal intervention. Distal 
protection is made more complex with a proximal renal artery bifurcation which would 
require two EPD devices (one in each branch) and an 0.035-in lumen balloon/stent 
catheter.   
A small randomized controlled study of 100 PTRAS patients were assigned to an 
open-label EPD or use of abciximab in a 2 x 2 factorial design.  A positive interaction 
was observed between treatment with abciximab and embolic protection.  PTRAS alone, 
stenting with an EPD, and stenting with abciximab were associated with similar and 
modest declines in eGFR at 1-month follow-up (-10, -12, -10 mL/min/1.73m
2
 eGFR 
change respectively); however, the group treated with both the EPD and abciximab was 
protected from a decline in eGFR and was superior to the other three groups (+9 
mL/min/1.73m2 eGFR change p<0.01)
65
.  
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In an uncontrolled retrospective trial, RFC were measured in 66 patients 
undergoing renal artery intervention with and without EPD. The EPD group had 
improved renal blood flow measured by RFC compared with the control group following 
RAS (Mean reduction in RFC 14.2 vs. 6.7 p=0.03)
66
. EPDs may be effective in 
preventing renal atheroembolic injury and a controlled trial measuring the impact of 
EPDs on renal blood flow following ARAS should be performed.  At present we reserve 
the use of EPD’s with renal stenting to patients with impaired renal function. 
Stent sizing with IVUS: IVUS provides more accurate anatomical characterization 
of the renal artery diameter. Twenty-two patients with atherosclerotic ARAS were 
studied with IVUS after pre-dilation and after angiographically successful stent 
deployment (diameter stenosis < 10%). Modification based on IVUS including selection 
of a larger balloon, additional dilation, and placement of a second stent occurred in five 
patients after pre-dilatation and one patient after stent deployment. The mean blood 
pressure and amount of antihypertensive drugs decreased (p < 0.05). Therefore, IVUS 
guidance during renal artery stent placement resulted in additional lumen enlargement not 
considered necessary at angiography
67
.  
 In a series of 363 renal artery interventions, follow-up angiography was available 
in 102 patients (34%) at an average of 303 days. Larger diameter arteries were associated 
with a significantly lower incidence of angiographic restenosis. The restenosis rate was 
36% for vessels with a reference diameter <4.5 mm compared with 16% in vessels with 
reference diameter 4.5 to 6 mm (p = 0.068) and 6.5% in vessels with reference diameter > 
6 mm (P < 0.01)
68
. IVUS allows a more accurate way to measure vessel diameter than 2D 
angiography, allowing the operator to safely maximize the stent size. Operaters may tend 
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to underestimate visual estimates to prevent complications related to over-sized balloons 
and stents, which can translate in higher rates of in-stent restenosis.  
Drug eluting stent (DES) vs. bare metal stent (BMS):  Restenosis after stent-
angioplasty of atherosclerotic RAS is a limitation, especially in small diameter renal 
arteries. Two meta-analyses of renal artery intervention with bare metal stents have 
demonstrated average restenosis rates after stent placement of 16% and 17%
41
.  
The GREAT study (Palmaz Genesis Peripheral Stainless Steel Balloon 
Expandable Stent, comparing a Sirolimus Coated with an Uncoated Stent in REnal Artery 
Treatment)
69
 was a prospective, multicenter study of angiographic patency of renal artery 
stents placed in 105 patients with atherosclerotic ARAS. The restenosis rate was 
determined as binary restenosis with a cut-off point at 50% diameter stenosis. The binary 
restenosis rate was 6.7% for sirolimus-eluting stents (SES) versus 14.6% for the bare 
metal stent (BMS) (p=0.30). After 6 months and 1 year, target lesion revascularization 
(TLR) rate was 7.7% and 11.5%, respectively, in the BMS group versus 1.9% at both 
time points in the SES group (p=0.21). This rate remained stable up to the 2-year follow-
up but did not reach significance due to the small sample size. Target lesion 
revascularization was performed in 8% of the patients in the BMS group, and 2% in the 
DES group. At 1-year follow-up, the clinical patency was 88.5% in the BMS and 98.1% 
in the DES group (P = 0.21).  
Restenosis lesions:  The durability of renal artery interventions is limited by the 
development of in-stent restenosis and the need for secondary or tertiary renal 
interventions. Renal stents have excellent long-term patency rates, with cumulative 
primary patency of 79% to 85% and a secondary patency of 92% to 98% at 5 years
70,71
.  
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The optimal treatment of renal artery in-stent restenosis is uncertain. Repeat renal 
artery stent placement demonstrated improved patency compared with balloon 
angioplasty alone with a 58% reduction in recurrent ISR (29.4% vs. 71.4%, P = 0.02). 
The repeat stent group also had better secondary patency (P = 0.05) and a greater 
freedom from repeat ISR (P = 0.01) when compared with balloon angioplasty alone. 
There was a trend favoring repeat stent placement for cumulative freedom from target 
vessel revascularization (TVR) (P = 0.08)
72
.  
The use of covered stents in the renal arteries has been reported in the 
management of complications including perforation
73
. Polytetrafluoroethylene (PTFE)-
covered stents and drug eluting stents may offer a way to treat recurrent renal artery 
stenosis. In a series of patients diagnosed having their at least second in-stent restenosis 
following renal artery stenting, covered stents had 17% (1/6) ISR at a mean follow up of 
36 months while drug eluting stents were free of ISR (0/10) 
74,75
. 
Follow up  
PTRAS patients should be followed at 1 month, 6 months and 1 year and annually 
thereafter for blood pressure control, with renal function testing and with surveillance 
DUS imaging 
76
. DUS is the recommended imaging technique to screen for in-stent 
restenosis. DUS surveillance monitoring for renal stent patency should take into account 
that a stented artery is less compliant than a native artery and that PSV and RAR obtained 
by DUS are higher for any given degree of arterial narrowing within the stent
23
, therefore, 
obtaining a post-procedure DUS is reasonable to establish a new baseline PSV.  
Conclusions 
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Patients with refractory uncontrolled renovascular hypertension despite maximal 
medical therapy, ischemic nephropathy and cardiac destabilization syndromes who have 
hemodynamically obstructive ARAS are likely to benefit from PTRAS. Screening for 
ARAS can be done with Doppler ultrasonography (DUS), computed tomographic 
angiography (CTA) and magnetic resonance angiography (MRA).  Currently the 
technical success for PTRAS (>97%) exceeds the percentage (~70%) of patients 
clinically responding. Physiologic measurements such as hyperemic/resting translesional 
gradients are useful to confirm the severity of renal hypoperfusion in moderate stenoses 
and therefore improve the selection patients likely to respond to renal artery 
revascularization. Experienced operators should perform renal interventions in order to 
minimize complications. Radial access should be preferred to avoid access related 
complications. Primary patency of appropriately sized and well placed BMS exceeds 
80% at 5 years and surveillance for in-stent restenosis can be done with periodic clinical, 
laboratory, and imaging follow-up. 
  
  25 
Tables: 
Table 1.  Outcome results for renal stents in hypertensive patients with unstable 
angina and congestive heart failure. 
 UNSTABLE ANGINA (n=23)  HEART FAILURE (n=25)  
 pre-
stent 
24 hr 6mo  pre-
stent 
24 hr 6mo  
Survival - 100% 96%  - 100% 88%  
Event-free - 100% 96%  - 100%   84%  
Sx  improved  - 91% 82%  -    76% 75%  
Functional 
class 
3.1±0.
7 
1.5±0.
8* 
1.5±1.
3* 
 3.2±0
.8 
1.8±0.9
* 
1.4±1.
4* 
 
SBP (mmHg) 176±2
4 
133±2
0* 
151±2
4* 
 163±
31 
128±19
* 
146±2
8* 
 
DBP (mmHg) 90±13 70±11
* 
81±11  83±1
7 
71±7* 75±15
* 
 
Serum Cr 
(mg%) 
1.5±0.
4 
1.6±0.
8 
1.7±0.
8 
 1.8±0
.4 
1.8±0.3 2.0±0.
6 
 
 
  SBP = systolic blood pressure, DBP = diastolic blood pressure; 
  * = p < 0.05 at 24 hr or 6 mo versus pre- stent value 
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Figure 1. Improvement in cardiac destabilization syndromes after renal artery 
revascularization. Khoshla et al. The American journal of cardiology. 1997;80:363-
366  
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Figure 2. Summary of initial reported series in terms of improvement of A. 
hypertension and B. renal function after renal artery revascularization. Despite a 
technical success of >95%, clinical outcomes did not match technical success. This 
suggests that selection of patients is crucial in order to obtain clinical benefit. 
 
 
  
  32 
Figure 3. Correlation between angiographic diameter stenosis and resting pressure 
gradient (BPG), Hyperemic pressure gradient (HPG) and Renal Fractional Flow 
Reserve (FFR). Subramanian et al. Catheter Cardiovasc Interv 2005;64:480–486  
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Figure 4. Correlation between Fractional Flow Reserve (FFR) and resting pressure 
gradient (BPG) (top) and hyperemic pressure gradient (HPG) (Bottom). 
Subramanian et al. Catheter Cardiovasc Interv 2005  
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Figure 5. Blood pressure improvement at follow-up stratified by baseline renal FFR 
(<0.8 vs. >=0.80). Mitchell et al. Catheterization and Cardiovascular Interventions 
69:685–689 (2007)  
 
 
